• CORRECTION: This story was updated on Jan. 7, 2016. Chakrapani Subramanyam received a Ph.D. from Pennsylvania State University, not the University of Pennsylvania.
Volume 94 Issue 1 | p. 32 | Awards
Issue Date: January 4, 2016

ACS Award For Team Innovation: Matthew F. Brown, Paul S. Changelian, Mark E. Flanagan, Michael J. Munchhof, and Chakrapani Subramanyam

Department: ACS News
Keywords: awards, 2016 ACS National Awards, people

Sponsor: ACS Corporation Associates

Citation: For work leading to the invention of Xeljanz (tofacitinib), the first JAK inhibitor to be approved for the treatment of rheumatoid arthritis.

What their colleagues say: “I sincerely believe that their landmark discovery of the first successful JAK inhibitor as an oral medicine for the treatment of rheumatoid arthritis is a dramatic medical advance, which will benefit countless humans for many years to come. I have followed this field and . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society